Approximately 1–4% of NSCLC cases exhibit HER2 mutations [140], and the expression of a HER2 mutant containing a 12 bp insertion at exon 20 (G776YVMA) was found to be more potent in BM than in wild-type HER2. Here, ERBB2 is linked to non-small cell lung carcinoma.